About Omass
Omass is a Healthcare company based in Oxford (United Kingdom) founded in 2016 by Jonathan Hopper and Idlir Liko, and was acquired by Syncona in November 2018. Native mass spectrometry services for protein characterization are provided. Omass has raised $19.32 million across 2 funding rounds from investors including Syncona and Oxford Science Enterprises. The company has 39 employees. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Analytical Testing. Its legal entity is OMASS THERAPEUTICS LIMITED. Its competitors include Crawford Scientific and Perfectus Biomed; 2 of its 2 listed competitors have raised funding.
Company details
Omass was established in 2016 in Oxford, United Kingdom, as a service provider in the pharmaceutical and research sectors. Native mass spectrometry is applied by the company to characterize intact protein assemblies, supporting drug discovery processes. Solutions are delivered through this specialized platform to clients in these industries, with operations focused on analytical services for protein-based research and development.
- Headquarters Oxford, United Kingdom
- Employees 39
- Founders Jonathan Hopper, Idlir Liko
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website omasstech.com
- Social LinkedIn X
- Acquired by Syncona (Nov 2018)
- Legal Name Omass Therapeutics Limited
- Date of Incorporation 26 Feb, 2016
- Jurisdiction OXFORD, ENGLAND
Funding Insights of Omass
Omass has successfully raised a total of $19.32M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $17.9 million completed in November 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $19.32M
- Total Rounds 2
- Last Round Series A — $17.9M
- First Round $1.42M
(Jun 2016)
- Investors Count 2
All 2 funding rounds of Omass with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2018 | $17.9M | Series A | – | Syncona, Oxford Science Enterprises | – |
| Jun 2016 | $1.42M | Seed | – | – |
2 investors in total: 2 institutional.
Investors in Omass
Omass has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Syncona and Oxford Science Enterprises.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare investments are managed via private equity by Syncona. | 2012 | synconaltd.com | London, United Kingdom | |
Investment management services for science ventures are provided in Oxford. | oxfordscienceenterprises.com | Oxford, United Kingdom |
Investor details for Omass
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Omass
2 people are tracked at Omass (2 in leadership); the tracked headcount is 39.
| Name | Role | Group |
|---|---|---|
Jonathan Hopper | Co-Founder & Vice President | Leadership |
Idlir Liko | Co-Founder & CTO | Leadership |
Complete people profiles for Omass
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Omass
4 dated milestones of Omass across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Omass is founded.
- Funding First funding round of $1.4M.
- Funding Latest funding round, Series A, of $17.9M.
- Exit Acquired by Syncona.
Competitors of Omass
Omass has 2 listed competitors in our database, 2 of them funded. They include Crawford Scientific and Perfectus Biomed.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| crawfordscientific.com | 1985 | Strathaven, United Kingdom | $9.78M | 50 | Service provider in analytical testing | |
| perfectusbiomed.com | 2012 | Daresbury, United Kingdom | $396,023 | 57 | Provides services for research-based approach for microbiological testing |
Detailed competitors of Omass
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Omass (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | |||
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Omass
Complete news archive for Omass
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Omass
Omass was founded in 2016.
Omass is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Omass is a funded company, having raised a total of $19.32M across 2 funding rounds to date. The company's 1st funding round was a Seed of $1.42M, raised on Jun 2016.
Omass has 39 employees.
Omass was established in 2016 in Oxford, United Kingdom, as a service provider in the pharmaceutical and research sectors. Native mass spectrometry is applied by the company to characterize intact protein assemblies, supporting drug discovery processes. Solutions are delivered through this specialized platform to clients in these industries, with operations focused on analytical services for protein-based research and development.
Omass's top competitors include Perfectus Biomed and Crawford Scientific.
Omass has 2 investors. Key investors include Syncona, and Oxford Science Enterprises.
Omass operates through Omass Therapeutics Limited.
Yes. Omass was acquired by Syncona in November 2018.